BioSpace News Archive

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has initiated the resubmission of its Biologics License Application for HIV under rolling review consistent with guidance from the U.S. Food and Drug Administration.

DNA Script, a leader in Enzymatic DNA Synthesis, announced that Blanche Savary de Beauregard has joined the company as General Counsel.

CB Scientific. Inc. is pleased to announce that it has submitted its application to uplist to the OTCQB® Venture Market.

ImmunoGen Inc. today announced that Kristen Harrington-Smith has been appointed Senior Vice President and Chief Commercial Officer.

Codiak BioSciences, Inc. today announced positive initial data for exoSTING, a novel engineered exosome therapeutic candidate currently being investigated in a Phase 1/2 clinical trial as a single agent for the treatment of multiple solid tumors.

GRO Biosciences Inc. today announced the hiring of veteran industry executive, Edward “Tad” Stewart , who joins the team as Chief Business Officer (CBO).

First Wave BioPharma, Inc. today announced that it has agreed with the former shareholders of First Wave Bio, Inc. (“FWB”) to amend the payment structure of the initial merger consideration and extend payments into 2023

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Frederick Lang, M.D., to its Oncology Advisory Board.

Vigeo Therapeutics today announced new clinical data from its Phase 1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with recurrent glioblastoma (rGBM).

Peloton Interactive, Inc. (“Peloton”) (Nasdaq: PTON) today announced that it has commenced an underwritten public offering of $1 billion of shares of its Class A common stock.